Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased ...

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

Health and Human Services Secretary Robert F. Kennedy, Jr. doubled down on his support for non-pharmaceutical health ...

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC ...

Increased consumption of phytosterols reduced the risk for CVD and type 2 diabetes, a study presented at the annual NUTRITION ...

This recent study introduces a non–insulin-specific version of the Diabetes Eating Problem Survey–Revised tool that screens ...

Biodexa Pharmaceuticals ( ($BDRX) ) just unveiled an announcement. On June 4, 2025, Biodexa Pharmaceuticals announced the recruitment of the first ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

TUCSON, AZ / ACCESS Newswire / June 2, 2025 / Umbrella Labs , a leading supplier of advanced research chemicals, announced the expansion of its peptide catalog to include Retatrutide (LY3437943), an ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Biocon has received approval in India for its generic version of Victoza, marking its first GLP-1 diabetes therapy clearance ...